1 / 12

GHRH

Growth Hormone. Insulin-related growth factor 1 (IGF-1) ( somatomedin C ). Serotoninergic. Adrenergic. Hypothalamus. GHRH. Somatostatin. -. +. +. +. Pituitary. +. Periphery. +. Epiphyses. Skeletal Muscle. Adipocytes. Growth. Lipolysis.

cleta
Télécharger la présentation

GHRH

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Growth Hormone Insulin-related growth factor 1 (IGF-1) (somatomedin C) Serotoninergic Adrenergic Hypothalamus GHRH Somatostatin - + + + Pituitary + Periphery + Epiphyses Skeletal Muscle Adipocytes Growth Lipolysis

  2. General Mechanisms of Releasing and Inhibiting Hormones in the Hypothalamic-Pituitary Axis TRH Inhib. Dopamine GHRH G G PL-C ATP 3’5’-cAMP

  3. Human Growth Hormone (HGH) • 191 amino acid peptide v.similar to prolactin and HCG. • Recombinant HGH 191 identical or 192 with added methionine. • Humans highly selective in responding only to HUMAN growth hormone amino acid sequence. • Other animal species don’t work. Bovine GH (as in US beef) has no known actions in humans. • Inactivated in gut if given orally: usually given sub-cutaneously. • T1/2endogenous HGHabout 25 min.

  4. Human Growth Hormone (HGH) Indications Growth Hormone Deficiency in Children • growth less than 4 cm/yr. and • failure to respond to stimulation (e.g hypoglycaemia, arginine,clonidine, etc.) Growth Hormone Deficient Adults • controversial Treatment of Catabolic States • ICU +/- parenteral nutrition (lipolysis to mobilise fat stores) • anabolic agent (e.g. Short bowel syndrome along with parenteral nutrition). Abuse • role as doping agent in sport is controversial.

  5. Human Growth Hormone (HGH) Adverse Effects • Creutzfeldt Jacob disease with pituitary extracts (until 1985). • Fluid retention (temporary). • Antibody formation (30% of patients) doesn’t affect efficacy. • Slipped epiphyses if growth response is very rapid. • Glucose intolerance • ?? Increased incidence leukaemia.

  6. Somatostatin(Growth Hormone Inhibiting Hormone) • Hypothalamic inhibitor of growth hormone release. • Also found in pancreas and GIT. • Also inhibits glucagon, insulin and gastrin release. • 14 amino acid peptide. • Very short T1/2(1-3 min) in plasma. Therapeutic Analogues Octreotide(8 amino acids) • T1/280 min • 45-times more potent than somatostatin Lanreotide • T1/24.5 days • fortnightly IM injections

  7. Somatostatin Analogues Octreotide and Lanreotide • Inhibit growth hormone secretion in acromegaly. • Cause tumour regression in acromegaly and prolactinoma. • Inhibit tumour growth in gastro-entero-pancreatic axis carcinoma (e.g. gastrinoma, glucagonoma, carcinoid tumours). • Inhibit endocrine-disorder induced diarrhoea. • Used with bleeding oesophageal varices (Octreotide) due to vasomotor effect in splanchnic circulation. • Adverse Effects: • glucose intolerance • gallstones

  8. Prolactin Serotoninergic Hypothalamus TRH Dopamine VIP - + + + OE Pituitary + OE Mammary Epithelium Progest. Insulin Periphery Milk

  9. Prolactin Therapeutic Uses / Preparations: • None Causes of Hyperprolactinaemia • Physiological (pregnancy & post-partum: oestrogen-stimulated) • Hypothyroidism (causing TRH excess) • Prolactinoma • Hypothalamic dopamine deficiency • Defective dopamine delivery • Lactotroph cells insensitivity to dopamine • Dopamine antagonists present Treatment of Hyperprolactinaemia • Correction of underlying cause • Dopamine analogues

  10. Dopamine Analogues Bromocriptine • Ergot peptide alkaloid • Highly selective dopamine receptor agonist. • Weak a-adrenergic and 5-HT agonist. • Inhibits Gi-protein coupled adenylyl cyclase • Inhibits prolactin release. • Inhibits growth hormone release, especially in GH-secreting tumours which co-secrete prolactin. Dosage • once - three times daily. • Safe in first 3-weeks of pregnancy Adverse Effects • nausea (stimulation of medullary vomiting centre). • Vasospasm at high dosage • Pulmonary infiltrate in chronic use.

  11. Dopamine Analogues Cabergoline • very long half-life of prolactin suppression allows twice-weekly dosage. • Less tendency than bromocriptine to cause nausea; probably better receptor selectivity. • Newer; less experience in early pregnancy; no reason to believe a problem exists. • Long-term adverse effects unknown

  12. Hyperprolactinaemia from Dopamine Antagonists Remember the following commonly used drugs may cause Hyperprolactinaemia: Dopamine antagonist Anti-nausea agents: e.g. • metoclopramide (e.g. Maxolon) • prochlorperazine (Stemetil) • domperidone (Motilium) Neuroleptics / Major tranquillisers e.g. • chlorpromazine • trazodone • prochlorperazine • thioridazine.

More Related